Market capitalization | DKK35.14b |
Enterprise Value | DKK26.99b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 484.61 |
P/S ratio (TTM) P/S ratio | 630.96 |
P/B ratio (TTM) P/B ratio | 4.13 |
Revenue growth (TTM) Revenue growth | -83.82% |
Revenue (TTM) Revenue | DKK55.69m |
As a Free StocksGuide user, you can view scores for all 6,836 stocks worldwide.
14 Analysts have issued a Zealand Pharma forecast:
14 Analysts have issued a Zealand Pharma forecast:
Mar '25 |
+/-
%
|
||
Revenue | 56 56 |
84%
84%
|
|
Gross Profit | 52 52 |
83%
83%
|
|
EBITDA | -1,377 -1,377 |
80%
80%
|
EBIT (Operating Income) EBIT | -1,402 -1,402 |
76%
76%
|
Net Profit | -1,186 -1,186 |
60%
60%
|
In millions DKK.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. Its products include Zegalogue and V-Go. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on April 1, 1997 and is headquartered in Soborg, Denmark.
Head office | Denmark |
CEO | Adam Steensberg |
Employees | 335 |
Founded | 1997 |
Website | www.zealandpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.